AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Rocket Pharmaceuticals Announces Participation at the Bank of America Merrill Lynch 2019 Healthcare Conference

May 7, 2019

NEW YORK--(BUSINESS WIRE)--May 7, 2019--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is scheduled to present on Wednesday, May 15, 2019, at 3:40p.m. Pacific Time at the Bank of America Merrill Lynch 2019 Healthcare Conference in Las Vegas, Nevada.

Gaurav Shah, M.D. will also participate in a Gene Therapy Panel on Wednesday, May 15, 2019, at 4:20p.m. Pacific Time

A live audio webcast of the presentation will be available on the Investors section of the company’s website,  www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Rocket’s additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for a devastating, pediatric heart failure indication, Danon disease. For more information about Rocket, please visit www.rocketpharma.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190507005196/en/

CONTACT: Claudine Prowse, Ph.D.

SVP, Strategy & Corporate Development

Rocket Pharma, Inc.

The Empire State Building, Suite 7530

New York, NY 10118

www.rocketpharma.com

investors@rocketpharma.com

KEYWORD: UNITED STATES NORTH AMERICA NEVADA NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY CLINICAL TRIALS GENETICS ONCOLOGY PHARMACEUTICAL PROFESSIONAL SERVICES BANKING FINANCE RESEARCH OTHER SCIENCE SCIENCE GENERAL HEALTH

SOURCE: Rocket Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 05/07/2019 07:00 AM/DISC: 05/07/2019 07:01 AM

http://www.businesswire.com/news/home/20190507005196/en